Peptide blend · Research Monograph · Two-peptide blend: GHK-Cu 50 mg + KPV 20 mg

GHK-Cu / KPV

Copper peptide + tripeptide blend · 70 mg lyophilized

This is a blend. GHK-Cu and KPV are combined in a single 70 mg vial at 50 mg and 20 mg respectively. GHK-Cu is a copper-binding tripeptide studied in skin-remodelling and matrix research; KPV is the C-terminal tripeptide of α-MSH studied for NF-κB pathway suppression. The pairing places a matrix-remodelling arm and an inflammatory-signalling arm in one vial. The combination has not been characterised as a single formulation.

Size
50mg / 20mg
Form
Lyophilized powder blend
View product & pricing → Lot records & COAs

For laboratory research use only - not for human or animal use

GHK-Cu / KPV vial from the Eon Peptides research catalog
GHK-Cu / KPV · 50mg / 20mg · catalog photograph
Available in the Eon catalog - GHK-Cu / KPV from $85.00

Molecular data

Physical formLyophilized powder blend
Available sizes50mg / 20mg

How it works

  1. GHK-Cu

    Copper Transport & Matrix Remodelling

    GHK-Cu is a copper-binding tripeptide. Collagen and glycosaminoglycan synthesis endpoints are characterised in dermal fibroblast culture, alongside copper-transport activity.

    • Copper-binding tripeptide
    • Collagen synthesis endpoints
    • Dermal fibroblast models
  2. KPV

    Inflammatory Pathway Suppression

    KPV is the C-terminal tripeptide of α-MSH. Lower NF-κB and MAP-kinase pathway activation is measured in vitro at nanomolar concentrations, alongside reduced TNF-α and IL-6 secretion.

    • α-MSH C-terminal fragment
    • NF-κB pathway suppression
    • Cytokine secretion endpoints
  3. Combined

    Matrix and Inflammatory Arms

    The vial pairs a matrix-remodelling arm with an inflammatory-signalling arm. Both are characterised separately; no interaction data exists for the pair.

    • Two complementary arms
    • Matched handling
    • Interaction not characterised

What the research shows

  1. Dermatology

    Skin Remodelling Models

    GHK-Cu is characterised for collagen and glycosaminoglycan synthesis in dermal fibroblast culture.

  2. Immunology

    Inflammatory Signalling

    KPV is studied for NF-κB pathway suppression and cytokine secretion endpoints.

  3. Dermatology

    Wound Closure Models

    Both peptides appear in wound-model literature from different mechanistic angles.

  4. Methods

    Parallel Protocols

    One vial holds both peptides under matched handling.

Specification

ComponentsGHK-Cu + KPV
Content70 mg per vial (50 mg GHK-Cu + 20 mg KPV)
GHK-Cu SequenceGly-His-Lys (copper complex)
KPV SequenceLys-Pro-Val (α-MSH 11-13)
KPV Molecular Weight342.43 g/mol
FormLyophilized powder blend
Purity≥99% by HPLC
SolubilityWater-soluble
Storage-20°C, protected from light
ClassificationResearch use only

Frequently asked questions

Why combine GHK-Cu and KPV?

They cover different arms of skin and inflammation research: GHK-Cu for matrix remodelling, KPV for inflammatory signalling. One vial holds both under matched handling.

Why is the ratio uneven?

The formulation is 50 mg GHK-Cu to 20 mg KPV, following the supplier's specification. It is fixed and cannot be varied within the vial.

Has the combination been characterised as a single formulation?

No. Each peptide is characterised separately and no interaction data exists for the pair.

What purity is documented?

Each lot is analysed by reverse-phase HPLC and released at ≥99%, with a Certificate of Analysis.

How is it stored?

Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.

  • KLOWFour-peptide blend · 80 mg lyophilized
  • BPC-157 / TB-500Two-peptide blend · 20 mg lyophilized
  • CJC / IPA BlendTwo-peptide blend · GHRH-R and GHS-R pathways
  • GlowThree-peptide blend · dermal and matrix models

For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.